Triple-Negative Breast Cancer

Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer characterized by the absence of three specific receptors commonly found in breast cancer: estrogen receptors, progesterone receptors, and excess human epidermal growth factor receptor 2 (HER2). This means that the cancer cells do not respond to hormonal therapies that target these receptors, making TNBC more challenging to treat compared to other breast cancer types. TNBC is often more aggressive, tends to grow and spread faster, and has a higher likelihood of recurrence. It is more prevalent in younger women, particularly those of African descent, and may exhibit distinct genetic features. Because of the lack of targeted therapies, treatment typically focuses on chemotherapy, and researchers are actively investigating new treatment options, including immunotherapy and targeted therapies specific to the genetic makeup of the tumors.